Search results
Original Medicare vs. Medicare Advantage: Which Should You Trust Your Health To?
Investopedia· 5 days agoIf you already have Medicare Parts A and B (or soon will), you can choose to receive your Medicare...
Amazon Pharmacy expands to Medicare enrollees
The Hill via AOL· 7 days agoAmazon Pharmacy will expand its subscription service to enrollees of Medicare insurance plans, the company announced Tuesday. The expansion will be...
Opinion: Silent crisis in rural America is Medicare's diminishing value post Inflation Reduction Act
Tulsa World· 5 days agoFor decades, Medicare has served as a crucial pillar of health care for America's seniors,...
Amazon Widens RxPass Eligibility To Include Prime Members With Medicare
Investopedia via Yahoo Finance· 7 days agoAmazon said Tuesday it is expanding eligibility for its $5 monthly Pharmacy RxPass subscription to...
Why COVID patients who could most benefit from Paxlovid still aren’t getting it
Daily Montanan via Yahoo News· 16 hours agoEvangelical minister Eddie Hyatt believes in the healing power of prayer but “also the medical...
What Makes United Health Group Incorporated (UNH) a Strong Buy?
Insider Monkey via Yahoo Finance· 14 hours agoWe recently compiled a list of the 10 Best Healthcare Stocks to Buy According to Hedge Funds. In...
Older Americans worry they can’t afford their own health care | CNN
CNN.com· 7 days agoTens of millions of seniors are similarly anxious about being able to afford health care because of...
Subtle victory for Sanders in Novo spat
Politico· 7 days agoBI makes the blockbuster diabetes drug Jardiance, one of the 10 products subject to the first tranche...population received opioid use disorder drugs and 6.2 percent filled ...
Humana (NYSE:HUM) Issues FY 2024 Earnings Guidance
ETF DAILY NEWS· 21 hours agoHumana (NYSE:HUM – Get Free Report) updated its FY 2024 earnings guidance on Monday. The Goldman Sachs Group lowered their price target on shares of Humana from $450.00 to $385.00 and set a ...
Gateway - Quartz
Quartz· 7 days agoThe first biosimilar to enter the market is Amgen’s Amjevita, which was launched in the US on Jan. 31, 2023. The drug will be available in the US at two ...